Once-Daily Treatment With Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder
Joel Young(Dalhousie University), Linda Wietecha(Eli Lilly (United States)), Elias Sarkis, Meihua Qiao(Eli Lilly (United States))
Cited by 61
Related Papers
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
|Brain|2019|275
Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
|CNS Spectrums|2009|93
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder
|Journal of the American Academy of Child & Adolescent Psychiatry|2015|63
Discontinuity in the Transition from Pediatric to Adult Health Care for Patients with Attention–Deficit/Hyperactivity Disorder
|Postgraduate Medicine|2012|49
Adult Attention-Deficit/Hyperactivity Disorder Diagnosis, Management, and Treatment in the <em>DSM-5</em> Era
|The Primary Care Companion For CNS Disorders|2016|45